GVK Biosciences forms alliance with Excel to conduct trials in India and China
GVK Biosciences (GVK Bio), an Asian integrated research services provider and Excel PharmaStudies (Excel), a Chinese clinical research organisation, are to carry out clinical trials in Asia.
GVK Biosciences (GVK Bio), an Asian integrated research services provider and Excel PharmaStudies (Excel), a Chinese clinical research organisation, are to carry out clinical trials in Asia.
The alliance will give access to the scientific skills, staff, flexible resourcing, and cost-effectiveness of both India and China. India has strength in Phase II/III clinical trials, while China is strong in its large market, Phase III and post marketing Phase IV studies.
Under the terms of the agreement, GVK Bio and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing. Any India trial for Excel will be carried out by the GVK Bio clinical research team and managed by a core project management team of Excel. Similarly, a GVK Bio China trial will be carried out by the Excel team and managed by GVK Bio's project management team.
"The GVK Bio-Excel alliance integrates trial management across India and China and provides sponsors with a single point of contact," said Manni Kantipudi, president of GVK Bio.
"It is an important step for Excel, and our clients, to be able to provide full services in both important countries," added Dr William Xiong, chief executive of Excel PharmaStudies.
The decision to form such an alliance comes close on the heels of GVK Bio's increased focus on clinical development. The company has recently strengthened its team by hiring Dr Shoibal Mukherjee, formerly with Pfizer, as its head of clinical development. GVK Bio has also added new services in pharmacovigilance and medical writing, operating from its clinical research facility in Gurgaon, India.